Abstract:Neuroprotection for ischemic stroke refers to strategies, applied singly or in combination, that antagonize the injurious biochemical and molecular events that eventuate in irreversible ischemic injury. There has been a recent explosion of interest in this field, with over 1000 experimental papers and over 400 clinical articles appearing within the past 6 years. These studies, in turn, are the outgrowth of three decades of investigative work to define the multiple mechanisms and mediators of ischemic brain injury, which constitute potential targets of neuroprotection. Rigorously conducted experimental studies in animal models of brain ischemia provide incontrovertible proof-of-principle that high-grade protection of the ischemic brain is an achievable goal. Nonetheless, many agents have been brought to clinical trial without a sufficiently compelling evidence-based pre-clinical foundation. At this writing, around 160 clinical trials of neuroprotection for ischemic stroke have been initiated. Of the approximately 120 completed trials, two-thirds were smaller early-phase safety-feasibility studies. The remaining one-third were typically larger (>200 subjects) phase II or III trials, but, disappointingly, only fewer than one-half of these administered neuroprotective therapy within the 4-6h therapeutic window within which efficacious neuroprotection is considered to be achievable. This fact alone helps to account for the abundance of "failed" trials. This review presents a close survey of the most extensively evaluated neuroprotective agents and classes and considers both the strengths and weakness of the pre-clinical evidence as well as the results and shortcomings of the clinical trials themselves. Among the agent-classes considered are calcium channel blockers; glutamate antagonists; GABA agonists; antioxidants/radical scavengers; phospholipid precursor; nitric oxide signal-transduction down-regulator; leukocyte inhibitors; hemodilution; and a miscellany of other agents. Among promising ongoing efforts, therapeutic hypothermia, high-dose human albumin therapy, and hyperacute magnesium therapy are considered in detail. The potential of combination therapies is highlighted. Issues of clinical-trial funding, the need for improved translational strategies and clinical-trial design, and "thinking outside the box" are emphasized.

Advances in Research of Neuroprotective Agents Treating Ischemic Stroke

Research Progress of Natural Products for the Treatment of Ischemic Stroke.

Research progress of natural products for the treatment of ischemic stroke

Network-Based Approach to Identify Potential Targets and Drugs That Promote Neuroprotection and Neurorepair in Acute Ischemic Stroke

Recent Progress in Research of Neuroprotective Drugs on Acute Ischemic Stroke

Advance in neuroprotective therapy for ischemic stroke

Recent advances in the development of neuroprotective agents and therapeutic targets in the treatment of cerebral ischemia

Advances in neuroprotective therapy for acute ischemic stroke

Current Status and Challenges in Neuroprotective Agents for Ischemic Stroke

Edaravone's free radical scavenging mechanisms of neuroprotection against cerebral ischemia: review of the literature

Advances in Stroke Pharmacology

Neuroprotective agents in acute ischemic stroke

Neuroprotection for ischemic stroke: Past, present and future

Targeted Therapy of Ischemic Stroke Via Crossing the Blood-Brain Barrier Using Edaravone-Loaded Multiresponsive Microgels.

The Research Progress of Drugs for Ischemic Stroke Treatment

The future of neuroprotection in stroke

Research Progress of Brain Ischemic Injury Protective Agents

Research Progress of Anti-stroke Medicine

Neuroprotective Phytochemicals in Experimental Ischemic Stroke: Mechanisms and Potential Clinical Applications

Emerging neuroprotective strategies for the treatment of ischemic stroke: An overview of clinical and preclinical studies